** Shares of drugmaker Ardelyx ARDX.O fall 21% to $5.04
** A court dismissed a lawsuit that company filed against the Centers for Medicare and Medicaid Services over their plan to include its kidney disease drug in the Medicare payment bundle system
** The drug, Xphozah, was approved in the US last year to treat high phosphate levels in patients with chronic kidney disease
** Brokerage Jefferies says focus is now back on Congress and if they can pass HR-5074 in about next 30 days
** The bill delays a change to the payment methodology under Medicare for oral drugs that are used to treat end-stage renal disease
** Stock down ~17% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。